JMP Securities lowered the firm’s price target on Integra LifeSciences to $49 from $55 and keeps an Outperform rating on the shares. The impact of the Boston facility being offline was evident in the Q4 results, as were some temporary throughput issues with Integra skin at one manufacturing line, with the latter already being largely addressed, the analyst tells investors in a research note. Initial 2024 guidance includes these headwinds, but also with them moderating and eventually clearing as the year progresses, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra Lifesciences Announces CEO Transition and New Executive Chairman
- Integra LifeSciences CEO Jan De Witte to retire by the end of 2024
- Integra LifeSciences sees Q1 adjusted EPS 53c-57c, consensus 74c
- Integra LifeSciences sees FY24 adjusted EPS $3.15-$3.25, consensus $3.44
- Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance